Home/Biosimilar Atlas/Companies/Bioeq

Bioeq

Biosimilar developer, Switzerland. 1 development product across 1 molecule: ranibizumab.

First approval in the Atlas: Aug 2022, Cimerli, ranibizumab (FDA)
FDAproducts approved1
EMAproducts approved1
MHRAproducts approved0
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered0
Connections
1molecule1product2 of 7markets0candidates in trials6companies on the same molecules

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
RanibizumabCimerli / Ranivisio FYB201Aug 2022Aug 2022·····2/7

Month shown is the first approval or registration of that product in that market.

In development

ClinicalTrials.gov lists three comparative trials sponsored by Bioeq for three molecules: aflibercept, ranibizumab, ustekinumab. All of these candidates already have at least one approval in the seven markets.

MoleculeCandidateDeveloper or sponsorReference productPhaseDesignRegistry statusStartedPrimary completionIn the AtlasRegistry record
AfliberceptFYB203BioeqEyleaPhase 3Comparative efficacyCompletedJul 2020Jun 2022Ahzantive / BaiamaNCT04522167
RanibizumabFYB201BioeqLucentisPhase 3Comparative efficacyCompletedDec 2015Dec 2017Cimerli / RanivisioNCT02611778
UstekinumabFYB202BioeqStelaraPhase 3Comparative efficacyCompletedNov 2020Jun 2021Otulfi / FymskinaNCT04595409

Registry data from ClinicalTrials.gov, entered by the sponsors and not verified by any regulator. Status and dates are as posted; sponsors often update them late. Trials registered only on other registries, such as India's CTRI or China's ChiCTR, are not included. Checked 12 Sep 2026.

Companies on the same molecules

Developers whose portfolios overlap most with Bioeq, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

Enzene BiosciencesOne shared molecule: ranibizumab6 molecules in its portfolioIntas PharmaceuticalsOne shared molecule: ranibizumab12 molecules in its portfolioLupinOne shared molecule: ranibizumab6 molecules in its portfolioQilu PharmaceuticalOne shared molecule: ranibizumab2 molecules in its portfolioReliance Life SciencesOne shared molecule: ranibizumab14 molecules in its portfolioSamsung BioepisOne shared molecule: ranibizumab10 molecules in its portfolio

Chronology

Compare Bioeq with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.